Evercore ISI Group Downgrades Chinook Therapeutics to In-Line, Announces $40 Price Target
Portfolio Pulse from richadhand@benzinga.com
Evercore ISI Group analyst Josh Schimmer downgrades Chinook Therapeutics (NASDAQ:KDNY) from Outperform to In-Line and announces a $40 price target.
June 14, 2023 | 1:19 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Chinook Therapeutics (KDNY) has been downgraded from Outperform to In-Line by Evercore ISI Group, with a $40 price target.
The downgrade from Outperform to In-Line by Evercore ISI Group indicates a less optimistic outlook for Chinook Therapeutics. This change in rating, along with the announcement of a $40 price target, could lead to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100